

Title page

Renal replacement therapies in neonates- issues and ethics

Professor Lesley Rees MD FRCPCH
Consultant in Paediatric Nephrology
Great Ormond Street Hospital for Children NHS Foundation Trust
Great Ormond Street
LONDON
WC1N 3JH

Tel. 0207 405 9200
Fax. 0207 829 8841

Abstract

Chronic irreversible kidney disease requiring dialysis is uncommon in the neonate. Many such neonates are diagnosed following antenatal US with congenital abnormalities of the kidneys and urinary tract (CAKUT). There is an increased incidence of prematurity and infants that are small for gestational age. Given the natural improvement in renal function that occurs in the neonatal period, some can, with careful management of fluid and electrolytes, be kept off dialysis until the creatinine reaches a nadir when a definitive plan can be made. There is a very high incidence of comorbidity and this affects survival, which overall is about 80% at 5 years. The multiple and complex ethical issues surrounding the management of these very young children are discussed.

Key Words

Neonate, kidney, chronic kidney disease, dialysis, survival, renal replacement therapy, ethics

Introduction

The numbers of neonates requiring dialysis for chronic, irreversible kidney disease (CKD) are extremely low. Most registries present data for under 2 year olds rather than neonates, for which figures vary from 7 to 12 per million age related population. For example that would be 20 to 30 at anytime in the UK, with a population of 64 million, and 100-150 in the US, with a population of 325 million. The European Society for Pediatric Nephrology and European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA), the International Pediatric Peritoneal Dialysis Network (IPPN) and Australia and New Zealand (ANZDATA) registries have looked to specifically identify neonates within the infant group. 264 neonates started chronic dialysis in 32 countries between 2000 and 2011. They represented around 18% of under 2 year olds on dialysis in both eastern and western Europe but only 6.8% in Australia and New Zealand. In Japan, neonates were 8.6% of dialysed children less than 5 years of age¹. These variations are likely to be related to local attitudes to termination of pregnancy following detection of a life threatening renal abnormality, attitudes to acceptance of such infants onto renal replacement therapy (RRT) programmes, and resources available. When dialysis is started is also dependent on local experience and policies.

The neonatal kidney

Kidney development commences at five weeks gestation. By week nine the first glomeruli are formed and by week 34 nephrogenesis ceases, by which time there are the definitive numbers of around one million glomeruli in each kidney. Therefore the premature infant's kidneys are particularly vulnerable to insult during the period of ongoing nephrogenesis. A bladder is detectable by week nine, and thereafter fetal urine contributes to over 90% of liquor volume.

90% of infants pass urine within 24 hours. Plasma creatinine reflects maternal levels at birth, and may rise in the first 3 weeks of life in premature infants due to tubular reabsorption.

Plasma bicarbonate may be lower than expected as the renal threshold for bicarbonate is 18-20mmol/l, rising to 24-26mmol/l by 1 year of age.

The neonate is predisposed to acute kidney injury (AKI). Fluid homeostasis is compromised because the kidneys receive only 15-20% of the cardiac output (25% in adults). The glomerular filtration rate (GFR) in the premature infant is 10-15 and 15-20 (ml/min/1.73m²) in the term infant. These values double over the first 2 weeks after birth and then rise progressively to adult values of 80-120 by 1 to 2 years of age. Maximum urine concentrating capacity is also low at birth (up to 600mOsm/kg) and increases over the first 2 months of life and then progressively over the first year of life

Factors predisposing the neonate with CKD to acute kidney injury (AKI)

The proportion of babies requiring RRT that are premature or small for gestational age (SGA) is higher than that in babies of the equivalent gestation without CKD. Up to one quarter is born prematurely and one fifth are SGA²⁻⁴ compared to around 8% in otherwise normal pregnancies⁵. These infants are therefore subject to all the complications associated with low birth weight, including chronic lung disease and developmental abnormalities, as well as the potential for insult to the ongoing nephrogenesis that continues up to 34 weeks gestation.

Premature and term neonates with CKD may have pulmonary hypoplasia, which occurs in association with oligohydramnios or grossly enlarged kidneys and are therefore more prone to birth asphyxia and chronic lung disease over and above the effects of prematurity. They are more likely to develop AKI due to exaggerated tubular electrolyte and water losses and dehydration, accompanying comorbidities, surgery, sepsis and the use of nephrotoxic drugs, which are all factors that are more common in the neonate with CKD⁶.

Common diagnoses in neonates requiring long term RRT

The majority of children in whom a need for RRT presents in the neonatal period have congenital abnormalities of the kidneys and urinary tract (CAKUT). Some children may have autosomal recessive polycystic kidney disease (ARPKD), with very large kidneys. Renal tubular dysgenesis is a rare cause. About 50% of these infants are diagnosed antenatally. This offers the benefits of antenatal counselling of families about the potential outcome of the pregnancy, and immediate optimization of medical intervention after birth. On the other hand we are not yet that good at predicting outcome on the basis of antenatal scans. Clearly the absence of kidneys is going to lead to a very bad prognosis, and often such foetuses do not survive or termination may be offered. However, foetal US and urinary investigations have not consistently been linked to outcome, and even oligohydramnios, which is believed to be a hard sign of poor outcome, is not always predictive⁷. Therefore the family has to live with uncertainty throughout the pregnancy.

When to start dialysis

A clear-cut need to start dialysis is unusual, unless there is renal or tubular agenesis or anuria. Many infants, particularly those with CAKUT, have ongoing urine production and

with attention to fluid and electrolyte balance and nutrition, can be kept without dialysis until they have recovered from respiratory complications or show improvement in kidney function, which would be expected in all neonates over the first few weeks of life. Indeed some babies may show a surprising improvement in renal function, and 10% of neonates actually stop dialysis¹. The extra time gained enables growth, postponing the technical difficulties associated with small size and allowing easier dialysis access. Indeed some babies may not need dialysis at all. It is a common concept that patients in renal failure need fluid restriction. However, for the child with CAKUT, this is rarely the case and is likely to worsen the situation. This is illustrated in case 1.

Case 1

A male foetus was diagnosed at 22 weeks with a left kidney with increased echogenicity, a right multicystic kidney and a thick walled bladder (Figure 1). There was oligohydramnios. He was born by spontaneous delivery at 33 weeks gestation, with a birth weight of 1.7kg. He did not require ventilation. He underwent urethral catheterisation, and was given IV fluids as 0.45% saline with dextrose, 80-100ml/kg/day. He was oliguric. His sodium and bicarbonate fell and his creatinine, potassium and urea rose progressively to reach 700 mcmol/l, 7.0mmol/l and 40mmol/l respectively by 2 weeks of age. Dialysis was not thought to be a possibility by the referring centre. He was referred to another centre for a second opinion. He was found to be dehydrated. He was started on IV normal saline, feeds at full requirement, and sodium and bicarbonate supplements. He began to gain weight and his creatinine fell progressively to 200 mcmol/l, with accompanying improvement in his potassium and urea levels. Dialysis was not necessary.

Prognostic indicators (Table 1)

As well as birth weight, gestation and pulmonary hypoplasia, there are other factors that impact on outcome and therefore influence the decision of the physician whether or not to recommend dialysis. The most important of these is co morbidity. Estimates suggest that this is present in as much as 73% of neonates requiring RRT^{1,8} and covers a complete spectrum of disabilities. Studies have linked comorbidity to poor outcome, with a five-fold higher mortality risk over 5 years in those with neurological disease¹ and an increase in mortality over 20 years of over seven-fold⁸. Those with CAKUT do better than those with ARPKD, in whom pulmonary hypoplasia and liver disease can cause serious comorbidity. The presence of long-term oliguria is also an adverse factor for outcome as it is at all ages. Finally, management of infants on RRT is laborious and is not possible without the full commitment of the family and the medical team⁹.

Resources (Table 2)¹⁰

The costs of RRT are substantial, and are particularly high in the infant, both in the short term because of the need for frequent reviews of the dialysis regimen, feeds and medications; and in the long-term because of the requirement for a lifetime of therapy. Such costs inevitably affect a country's ability to treat these infants, depending on available resources. Table 2 shows IPPN data on the number of children taken onto RRT programmes according to the gross national income per capita of the country. When this falls below \$12,000, numbers of young children on RRT programmes drop significantly¹⁰.

Survival of neonates on RRT (figure 2).

Survival of very young children on dialysis is good and similar to that in older children when the effects of comorbidity are removed⁸. Figure 2 shows the survival to age 5 years for the recent combined registries neonatal data between the years 2000 and 2011¹, of US neonates and 1 month to 2 year olds in the era 1992 to 2005¹¹, and a further analysis over 3 years in the US for the era 2000-2012¹². The first thing to notice is that the survival of the neonates is similar to that of the 1 month to 2 year olds. The second is that the recent cohorts seems to have a better survival than the older ones, being 80% at 5 years in the combined registries and also 80% at 3 years in the US. This had been 60% at 5 years between 1992 and 2005, and this improvement is statistically significant¹². However, the data has to be viewed in the context that, like all registries, we do not know its completeness. It is likely that not only have the sickest children been excluded, but also that others with equally poor renal function may not have been included because of purposeful delay in initiating dialysis. The importance of this is that the missing data will influence the survival and causes of death in the cohorts that have been treated. Despite that, these data is very helpful when counseling families about the prognosis for their child.

Health related quality of life (HRQoL)

The outcome for the future quality of life for the newborn is another important question that families want answered. In a follow up study of 41 young adults who had CKD stage 4/5 from infancy, 13% were on dialysis and 87% had a transplant at the time of the analysis. 54% had co-morbidities. Lower HRQoL scores were associated with co-morbidities, being on dialysis, more than one treatment modality change and being of short stature. Compared to a healthy, age matched population, employment rates and educational were levels similar although HRQoL was lower in physical and social role limitation and general health perception. The scores were comparable to those needing RRT in later childhood¹³. Again, these data is very helpful when counseling families about the prognosis for their child.

Ethical aspects of RRT in infants

The decision as to whether to start RRT in the neonate can be fraught with complex ethical issues, particularly in the child with comorbidities that also affect their survival and quality of life, and in parts of the world with limited resources. The European Paediatric Dialysis Working Group Guidelines, drawn up in 2014, state that when deciding whether to start RRT in the infant, comorbidities, predicted quality of life for the child and family, availability of resources (both medical and those of the family support structure) and the prognosis and possibility for future transplantation should be taken into consideration. The guidelines also recommend that parents of the affected child should be actively involved in the decision-making process¹⁴. Even with these guidelines it can be very difficult to decide whether RRT is the best and most appropriate next step and agreement between the parents and the medical team is not always the case.

Views of paediatric nephrologists and the multidisciplinary team on starting RRT in neonates and infants

Even in well-resourced countries there is ambiguity amongst paediatric nephrologists as to whether RRT is justified in all newborn that require it, and particularly so in those with comorbidity¹⁵. In a survey of pediatric nephrology teams in Canada, Germany, Japan, the United Kingdom, and the United States in 2010, 30% of paediatric nephrologists said they would offer RRT to all neonates and 50% to all infants aged one to 12 months. 50% believed that parents can never refuse RRT for children aged 1 to 12 months, compared with 27% for younger infants. The most influential factor in rejecting RRT for infants was comorbidity. Interestingly, nurses were more likely to believe that parents have the right to refuse RRT for infants. Comorbidity was the commonest cause given for the reason not to treat. 73% believed that parents can refuse RRT in the neonate¹⁵.

In a more recent survey of paediatric nephrologists undertaken at the ESPN annual meeting in 2012, 12% said they would recommend RRT to all neonates with ESKD and 5% said they would not offer it at all. However, for infants aged 1 to 12 months, opinions changed such that 31% would recommend RRT for all and no one stated that they would not offer it at all to any infant. 72% thought it was usually acceptable for parents to refuse treatment for their newborn, whereas only 50% thought this is acceptable for those ages 1 to 12 months. The reasons for this difference in attitude to neonates in comparison to infants are not clear, and are in contrast to a recent eloquent discussion of ethical issues in the neonate, which makes very forcefully the argument that a decision to treat a neonate differently from an older child is unjustified¹⁶. Factors affecting the decision making process were ranked as follows: coexistent serious medical abnormalities the highest, followed by anticipated morbidity for a child, the family's right to decide, the doctor's/medical staff's right to decide, the presence of oligoanuria, family socioeconomic status and finally hospital/government budget constraints (personal data, F Emma, L Rees).

The role of ethics in decision making

So, can ethics help us when faced with these circumstances? Ethics are a set of principles that distinguish between right and wrong. However, rarely is there one single 'right' way to do something. Ethics therefore provide a means of evaluating and choosing between different, often competing options and are about analysing values rather than facts.

The UK Royal College of Paediatrics and Child Health have produced guidelines on withholding and withdrawing life-saving treatment. The guidelines state that treatments, now and in the future, must be 'in the child's best interests'. They also state that 'It is ethically acceptable to limit treatment that is not in a child's best interests'¹⁷. An action or intervention is defined as being in the child's best interests if the benefits outweigh burdens, there is acceptable minimisation of harm, the child is treated fairly and justly and, in the case of older children, there is respect for as much autonomy (capacity for self-directed, informed choice) as the individual is capable of exercising. However, sources of ethical conflict are rarely that simple to resolve.

The French Neonatal Society states that assessment of the child's future quality of life, rather than its chances of survival, is the determinant of whether lifesaving treatment is reasonable or unreasonable, i.e. in the child's best interests¹⁸. The Nuffield Council on

Bioethics (UK) definitions of quality of life include survival without life support, life outside of hospital, ability to develop relationships and ability to gain pleasure from life¹⁹.

Sources of ethical conflict

As well as withholding or withdrawing life sustaining therapies, there are additional situations when ethical conflicts can arise. Amongst these are when application of clinical facts alone cannot determine what should be done, when there is disagreement about the right course of action; and when application of moral principles conflict. Below are some examples of such ethical conflicts.

Case 2: Application of clinical facts alone cannot determine what should be done:

Failure of PD access has made PD an impossibility for the future, and the only option is HD:

A baby with an antenatal diagnosis of posterior urethral valves with severe oligohydramnios at 22 weeks was delivered following spontaneous onset of labour at 32 weeks. The birth weight was 2.4kg. A PD catheter was inserted on day 3 of life due to anuria. There was leakage around the catheter and it had to be changed on day 5 of life. The baby developed necrotizing enterocolitis with gangrenous gut and a severe peritonitis requiring catheter removal. The only option was haemodialysis in this small infant whose peritoneum was unlikely to recover for use in the future. Should HD be recommended or should treatment be withdrawn at this stage?

Case 3 There is disagreement about the right course of action

Removal of kidneys in a child with Congenital Nephrotic Syndrome or ARPKD, considered to be lifesaving by the medical team, conflicts with parental views

Termination was recommended following an antenatal diagnosis at 20 weeks gestation of bilateral large, bright kidneys with oligohydramnios. The parents rejected termination. The infant was delivered at 36 weeks gestation with a birth weight of 2.8kg. He required resuscitation and high frequency oscillation. The kidneys filled the abdomen but the urine output was good (Figure 2). The baby could not be maintained without ventilation because of diaphragmatic compression by the kidneys. The parents refused the recommendation for nephrectomies.

Case 3 Application of moral principles conflict

Treatment of the child with severe co-morbidity

An infant was born with multiple complex abnormalities including abnormal vision and hearing, cardiac abnormalities, microcephaly and bilateral renal abnormalities. The child needed dialysis but the medical staff believed that this would not be appropriate. The parents want all possible treatments to proceed.

The law may be unhelpful in these situations. Although deliberate intention to cause or hasten a patient's death (euthanasia) is illegal, decisions about withholding or withdrawing

treatment are less black and white, and ethical conflicts require professionals to make value judgments to resolve them. Many hospitals have 'ethical committees' whose purpose is to lead and aid discussions about difficult cases, but they are for guidance rather than decision making.

Is withholding or withdrawing life sustaining treatments ever acceptable?

The French Neonatal Society Recommendations state that 'Withholding or withdrawing life-sustaining treatment may be acceptable, and unreasonable therapeutic obstinacy is condemned. To withhold or withdraw a life-sustaining treatment can be justified when the intention is to cease opposing, in an unreasonable manner, the natural course of a disease'¹⁸. A particularly difficult concept for affluent areas is the role of resources in the decision making process. Clearly there are countries who do not have the resources to support such expensive treatments. In 1995 UK neonatologists wrote that 'It may well be ethical to withdraw [or withhold or limit] treatment on the grounds that greater benefit could be achieved by using the resources in other ways'²⁰. Nearly twenty years later the debate continues, but there is not a country in the world that does not have to ration treatments in some ways.

Conflicts in decision making responsibilities

There is no international concordance about who should be responsible for decision making in ethical disputes, and opinions vary between countries. The US Presidential Commission for the Study of Bioethical Issues is an advisory panel of the nation's leaders in medicine, science, ethics, religion, law, and engineering. The Bioethics Commission seeks to identify and promote policies and practices that ensure scientific research, health care delivery, and technological innovation are conducted in a socially and ethically responsible manner. The commission has divided ethical issues about treatment management into into 3 neat categories: those that are clearly beneficial, when treatment should be provided even if the parents do not consent; those that are clearly futile, when treatment should not be provided, even if parents want it; and those when outcomes are ambiguous or uncertain, when parents should be the final determiners of course of action²¹. However, although these guidelines are very neat they are over simplistic and it is rarely possible to make such distinctions. The French Neonatology Society recommends that although the parents must be involved in the decision process so that they form an alliance with the healthcare team, any crucial decision affecting the patient's life calls for individual medical responsibility¹⁸.

Are neonates treated differently to infants, older children and adults?

In 1995 it was written that 'Clinicians frequently give young patients more chances to revive from and survive their illnesses than they offer to older, particularly elderly, patients. Clinicians also seem more willing to impose greater burdens on children with fewer chances of success than adults.' Conversely, a more recent review stated that 'Dialysis is not a therapy that doctors feel to be morally obligatory in most cases. While many doctors recommend dialysis for most infants with ESKD, most are willing to provide only palliative care if that is what the parents want'¹⁶. The conflicting nature of these statements reflect the individuality of each case such that generalisations are not possible or appropriate.

Conclusion

The number of neonates requiring RRT is small. However, their outcome is good, and equal to that of infants, providing that they do not suffer from comorbidities. Ethical issues are complex and every chosen pathway must be in the child's best interests.

References

1. Van Stralen KJ, Borzych-Duzalka D, Hataya H et al: Survival and outcomes of children starting renal replacement therapy in the neonatal period. *Kidney Int* 2014;86:168-74
2. Mekhali D, Shaw V, Ledermann SE, Rees L: Long-term outcome of infants with severe chronic kidney disease. *Clin J Am Soc Nephrol* 5:10–17, 2010
3. Rees L, Azocar M, Borzych D, et al. for the International Pediatric Peritoneal Dialysis Network (IPPN) registry. Growth in Very Young Children Undergoing Chronic Peritoneal Dialysis. *Journal of the American Society of Nephrology* 2011;22:2303-2312
4. Laakkonen H, Happonen JM, Marttinen E, et al. Normal growth and intravascular volume status with good metabolic control during peritoneal dialysis in infancy. *Pediatr Nephrol* 2010 ;25:1529-38
5. Greenbaum LA, Muñoz A, Schneider MF, et al. The association between abnormal birth history and growth in children with CKD. *Clin J Am Soc Nephrol* 2011;6:14-21
6. Rees L. Infant dialysis. What makes it special? *Nature Rev Nephrol* 2013; 9:15–17
7. Hogan J, Dourthe ME, Blondiaux E et al. Renal outcome in children with antenatal diagnosis of severe CAKUT. *Pediatr Nephrol* 2012; 27,:497–502
8. Shroff R, Rees L, Trompeter RS, Hutchinson C, Ledermann S. Long-term outcome of chronic dialysis in children. *Pediatr Nephrol* 2005;21:257–264
9. Rees L. The dilemmas surrounding the decision to start chronic dialysis in the neonate. *Kidney Int* 2014;86:18-20 Impact of global economic disparities on practices and outcomes of chronic peritoneal dialysis in children: insights from the International Pediatric Peritoneal Dialysis Network Registry.
10. Schaefer F, Borzych-Duzalka D, Azocar M, et al. Impact of global economic disparities on practices and outcomes of chronic peritoneal dialysis in children: insights from the International Pediatric Peritoneal Dialysis Network Registry. *Perit Dial Int* 2012;32:399-409.
11. Carey WA, Talley LI, Sehring S A, Jaskula J M, Mathias RS: Outcomes of dialysis initiated during the neonatal period for treatment of end-stage renal disease: a North American Pediatric Renal Trials and Collaborative Studies special analysis. *Pediatrics* 119: e468–e473, 2007
12. Carey WA, Martz KL, Warady BA. Outcome of Patients Initiating Chronic Peritoneal Dialysis During the First Year of Life. *Pediatrics* 2015;136(3):e615-22
13. Mekahli D, Ledermann S, Gullett A, Rees L. Evaluation of quality of life by young adult survivors of severe chronic kidney disease in infancy. *Pediatr Nephrol* 2014;29:1387-93
14. Zurowska A M, Fischbach M, Watson AR, Edefonti A, Stefanidis C J, on behalf of the European Paediatric Dialysis Working Group: Clinical practice recommendations for the care of infants with stage 5 chronic kidney disease (CKD5). *Pediatr Nephrol* 2013;28:1739-48

15. Teh JC, Frieling ML, Sienna JL, Geary DF. Attitudes of care givers to management of end-stage renal disease in infants. *Perit Dial Int* 2011;31:459-465
16. Lantos JD, Warady BA. The evolving ethics of infant dialysis. *Pediatr Nephrol* 2013; 28:1943-7
17. Withholding or Withdrawing Life Sustaining Treatment in Children. A Framework for Practice, RCPCH London 2015
18. Dageville C, Bétrémieux P, Gold F, Simeoni U, for the Working Group on Ethical Issues in Perinatology. The French Society of Neonatology's Proposals for Neonatal End-of-Life Decision-Making. *Neonatology* 2011;100:206–214
19. Nuffield Council on Bioethics (UK): Critical care decisions in fetal and neonatal medicine: ethical issues. November 16, 2006. <http://www.nuffieldbioethics.org>
20. Stevenson RC, Cooke RWI. Economics and ethics in neonatology. *Seminar Neonatol* 1998; 3; 315-321
21. Summaries of the reports from the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. <http://web.utk.edu/~ggraber/GBEa2.pdf>
22. Nelson LJ, Hylton Rushton C, Cranford RE, Nelson RM, Glover JJ, Truog RD. Foregoing medically provided nutrition and hydration in paediatric patients. *J Law Med Ethics* 1995;23:33-46

Table 1 Factors affecting the prognosis of neonates needing RRT

Birth weight and gestation
Co-morbidity
Aetiology of CKD
Pulmonary hypoplasia
Oliguria/residual renal function
Family circumstances

Table 2 Effect of gross national income on numbers of young children taken onto RRT programmes¹⁰

| Age at start of dialysis | Gross national income in \$000s per capita | | | |
|--------------------------|--|-------|-------|-----|
| | >28 | 18-28 | 12-18 | <12 |
| <1 year | 19 | 18 | 16 | 2 |
| 1–3 years | 11 | 15 | 11 | 6 |

Figure 1 Antenatal US of a male foetus with a left kidney with increased echogenicity and a right multicystic kidney.



Figure 2. Survival of neonates and infants during 2 different eras in the US and ESPN/EDTA-ERA, ANZDATA and Japanese registries.




Figure 3. Nephromegaly in a child with ARPKD, causing respiratory depression.

